Study Summary
The purpose of this study is to estimate the safety and the efficacy of anti-CD19/22 CAR- T cells immunotherapy for adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.
Want to learn more about this trial?
Request More InfoInterventions
CD19/22 CAR-T cellsBIOLOGICAL
Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 150 x 10⁶ CD19/CD22 CAR-T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| State Institution Minsk Scientific and Practical Center for Surgery, Transplantology, and Dermatology | Minsk | Belarus |